Since then, there have been slight indications of favorable outcomes with anti-PD-L1 inhibitors such as atezolizumab compared to anti-PD-1 inhibitors in pretreated advanced NSCLC patients [12]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.